Thermo Fisher Scientific (TMO) Receivables - Other (2018 - 2026)

Thermo Fisher Scientific has reported Receivables - Other for 9 years, with the latest figure at $1.7 billion in Q2 2026.

• Receivables - Other for Q2 2026 came in at $1.7 billion, up 17.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 17.14% YoY), and the FY2025 annual result was $1.7 billion, up 16.1% from the prior year.
• Receivables - Other steadied at $1.7 billion in Q2 2026, from $1.7 billion in the prior quarter.
• Over five years, Receivables - Other peaked at $1.7 billion in Q2 2026 and troughed at $1.1 billion in Q2 2022.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2023 frame the typical range for Receivables - Other.
• The widest annual swing landed in 2022, when Receivables - Other soared 54.46%; it then declined 3.94% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.3 billion in 2022, then advanced by 9.98% to $1.4 billion in 2023, then fell by 0.55% to $1.4 billion in 2024, then gained by 16.1% to $1.7 billion in 2025, then gained by 1.32% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.7 billion in Q2 2026, $1.7 billion in Q1 2026, and $1.7 billion in Q4 2025.